Yamini Ohol
About Yamini Ohol
Yamini Ohol is a Principal Scientist at Bristol Myers Squibb with extensive experience in oncology and immuno-oncology research.
Current Position at Bristol Myers Squibb
Yamini Ohol currently holds the position of Principal Scientist at Bristol Myers Squibb. In this role, she is responsible for overseeing various aspects of oncology drug discovery. She leads a team of three, managing program strategies to ensure successful achievement of preclinical development goals. Her responsibilities also include ensuring high productivity and implementing effective strategies within her team.
Experience at RAPT Therapeutics
Prior to her current role, Yamini Ohol worked at RAPT Therapeutics where she held several key positions. From 2019 to 2021, she served as a Senior Scientist and Project Team Lead in the San Francisco Bay Area. She also worked as a Scientist II and Project Team Lead from 2016 to 2018 in South San Francisco, CA. In these roles, she was involved in novel target discovery and validation, focusing specifically on oncology and immuno-oncology.
Previous Roles at 3-V Biosciences and Merck
Yamini Ohol has also worked as a Senior Scientist at 3-V Biosciences from 2012 to 2015 in Menlo Park, CA. Before this, she was a Post-Doctoral Researcher at Merck (formerly Schering-Plough/DNAX) from 2009 to 2012 in Palo Alto, CA. Her work in these roles contributed to her extensive background in primary immune cell assays, high-throughput cell-based assays, and gene and protein expression analysis.
Academic Background and Research at UCSF and Wellesley College
Yamini Ohol completed her Ph.D. at the University of California, San Francisco, where she engaged in Doctoral Research from 2002 to 2009. She earned her Bachelor of Arts degree from Wellesley College, where she also conducted undergraduate research from 2000 to 2002. Her academic and research experiences have laid a solid foundation for her expertise in oncology and immuno-oncology.
Technical Expertise in Oncology Drug Discovery
Yamini Ohol possesses a wide range of technical expertise crucial for oncology drug discovery. Her skills include primary immune cell assays (both human and mouse), high-throughput cell-based assays, and gene and protein expression analysis. She also has extensive experience in outlining and implementing program strategies to achieve preclinical development goals in oncology drug discovery.